Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 3/2018

01-06-2018 | Case Report

Dacryoendoscopy-guided transcanalicular intralesional interferon alpha 2b for canalicular squamous papillomas

Authors: Mohammad Javed Ali, Swati Singh, Anasua Ganguly, Milind N. Naik

Published in: International Ophthalmology | Issue 3/2018

Login to get access

Abstract

Canalicular papillomatosis is a rare disorder characterized by a mass lesion arising from the epithelium as a stalk from one of the canalicular walls. Traditionally, they have been treated with an open canaliculotomy and excision biopsy with or without additional cryotherapy. A patient with upper canalicular squamous papillomas treated with dacryoendoscopy-guided transcanalicular intralesional and topical interferon alpha 2b is presented, and the ineffectiveness of interferons in this case is discussed.
Literature
1.
2.
Lass JH, Grove AS, Papale JJ et al (1983) Detection of human papilloma virus DNA. Sequence is conjunctival papilloma. Am J Ophthalmol 96:670–674CrossRefPubMed
3.
Migliori ME, Putterman AM (1990) Recurrent conjunctival papilloma causing nasolacrimal duct obstruction. Am J Ophthalmol 110:17–22CrossRefPubMed
4.
Slade CS, Katz NN, Whitmore PV, Bardenstein DS (1988) Conjunctival and canalicular papillomas and ichthyosis vulgaris. Ann Ophthalmol 20:251–255PubMed
5.
Siedlecki AN, Tapp S, Tosteson AN et al (2016) Surgery versus interferon alpha 2b treatment strategies for ocular surface squamous neoplasia: a literature based decision analysis. Cornea 35:613–618CrossRefPubMedPubMedCentral
6.
Karp CL, Garol A, Chhabra S et al (2010) Subconjunctival/perilesional recombinant interferon alpha 2b for ocular surface squamous neoplasia: a 10 year review. Ophthalmology 117:2241–2246CrossRefPubMed
7.
Bracarda S, Eggermont AM, Samuelsson J (2010) Redefining the role of interferons in the treatment of malignant diseases. Eur J Cancer 46:284–297CrossRefPubMed
Metadata
Title
Dacryoendoscopy-guided transcanalicular intralesional interferon alpha 2b for canalicular squamous papillomas
Authors
Mohammad Javed Ali
Swati Singh
Anasua Ganguly
Milind N. Naik
Publication date
01-06-2018
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 3/2018
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0572-9

Other articles of this Issue 3/2018

International Ophthalmology 3/2018 Go to the issue

Original Paper

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Original Paper

Performing corneal crosslinking under local anaesthesia in patients with Down syndrome

Case Report

Double bubble with the big-bubble technique during deep anterior lamellar keratoplasty

Original Paper

Correlation between morphological changes and functional outcomes of recent-onset macula-off rhegmatogenous retinal detachment: prognostic factors in rhegmatogenous retinal detachment

Original Paper

Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

Original Paper

Hydroxypropyl methylcellulose 2% for dry eye prevention during phacoemulsification in senile and diabetic patients